Phaseline

Companies › Encoded Therapeutics

Encoded Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Neurology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ETX101
AAV9-delivered gene therapy encoding engineered transcription factor (eTFSCN1A) to increas
Ion channelsPhase 1Dravet SyndromeJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05419492ETX101Phase 1Dravet SyndromeNeurologyJun 2028
NCT06112275ETX101Phase 1Dravet SyndromeNeurologySep 2030
NCT06283212ETX101Phase 1Dravet SyndromeNeurologyOct 2030

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine Industrial Farmacéutica Cantabria

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.